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Objective Population-based studies demonstrating the clinical impact of interferon-free direct-acting 
antiviral (DAA) therapies are lacking. We examined the impact of the introduction of DAAs on HCV-
related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.  
Design Through analysis of national surveillance data (involving linkage of HCV diagnosis and 
clinical databases to hospital and deaths registers), we determined i) the scale-up in the number of 
patients treated and achieving a sustained viral response (SVR), and ii) the change in the trend of new 
presentations with HCV-related DC, with the introduction of DAAs.  
 
Results Approximately 11000 patients had been treated in Scotland over the eight-year period 
2010/11 to 2017/18. The scale-up in the number of patients achieving SVR between the pre-DAA and 
DAA eras was 2·3-fold overall and 5·9-fold among those with compensated cirrhosis (the group at 
immediate risk of developing DC). In the pre-DAA era, the annual number of HCV-related DC 
presentations increased 4·6-fold between 2000 (30) and 2014 (142). In the DAA era, presentations 
decreased by 51% to 69 in 2018 (and by 67% among those with chronic infection at presentation), 
representing a significant change in trend (rate ratio 0·88, 95% CI 0·85 to 0·90). With the introduction 
of DAAs, an estimated 330 DC cases had been averted during 2015-18.  
Conclusions National scale-up in interferon-free DAA treatment is associated with the rapid 
downturn in presentations of HCV-related DC at the population-level. Major progress in averting 






Significance of this study 
 
What is already known on this subject? 
 Decompensated cirrhosis (DC) is the major sequelae of chronic hepatitis C virus (HCV) infection, 
accounting for the majority (65%) of the 400,000 HCV related-deaths occurring worldwide each 
year.  
 Cohort studies have demonstrated that exposure to new direct-acting antivirals (DAAs) for 
chronic HCV to be associated with a decrease in all-cause mortality and hepatocellular carcinoma, 
but findings were inconclusive for DC.  
 Studies showing the population-level impact of DAAs on chronic HCV-related sequelae are 
lacking.  
 
What are the new findings?  
 At a population-level, new presentations of chronic HCV-related DC fell by 67% within the first 
four years of DAAs, contemporaneous with national scale-up of these new therapies in Scotland. 
 For newly diagnosed compensated cirrhotic patients, the risk of presenting with DC was halved in 
the DAA, compared to pre-DAA, era. 
Implications of all the available evidence  
 Countries should aim to make major progress in averting HCV-related DC, ahead of WHO global 





Worldwide, 71 million people are estimated to be living with the hepatitis C virus (HCV).1 In the 
absence of therapeutic intervention, chronic HCV infection can lead to compensated cirrhosis (CC), a 
generally asymptomatic state until onset of severe sequelae, notably decompensated cirrhosis (DC).2 
The latter is life-threatening, requiring liver transplantation to avoid an otherwise 70% mortality risk 
within five years.3 Cirrhosis thus accounts for the majority (65%) of the 400,000 HCV-related deaths 
worldwide each year.1  
The new generation of direct-acting antiviral (DAA) drugs for HCV are extraordinarily 
effective, well-tolerated and of short (8-12 week) duration.4 Carefully conducted clinical trials and 
real-world studies have demonstrated the ability of DAAs to clear HCV from the host, resulting in a 
sustained viral response (SVR) in excess of 90% of patients’ treated.5,6 In the pre-DAA era, SVR 
achievement was associated with approximately 80% reduction in risk for severe liver outcomes.7,8 
Treatment with DAA therapy has therefore the potential to profoundly change the course of rising 
trends in HCV-related disease burden.9,10 However, the clinical utility of a DAA-induced SVR has 
been disputed by authors of a Cochrane review who have advocated that the real-world impact of 
DAA therapy on HCV-related liver morbidity remains unproven.11,12 Data from population-based 
studies are thus in demand to corroborate the expected clinical benefit from these drugs.13,14,15 
Due to the high cost of DAA drugs and large number of people infected, Scotland, like many 
other countries, initially prioritised patients with advanced liver fibrosis; in addition, an ambitious 
government target was set, informed by mathematical modelling, to reduce the number of new 
presentations for HCV-related DC nationally by 75% within five years.9,16 Scotland – through 
establishment of national surveillance of HCV, unparalleled elsewhere, covering diagnoses, treatment 
and disease – is well placed to assess the population impact of DAAs on hepatic sequelae.17 Herein, 
we evaluated the early impact of Scotland’s strategy, in relation to the introduction of interferon-free 
DAA therapy, on i) the scale-up of patients treated for HCV and achieving SVR (particularly among 
those with CC, the group at immediate risk of developing DC), and ii) new presentations with HCV-




Through analysis of national surveillance data, we examined changes over time in the uptake and 
impact of HCV treatment in Scotland. As previous modelling work had indicated that a three-fold 
increase in HCV treatment among those with advanced liver fibrosis could lead to immediate impact 
in preventing HCV-related DC,9 we gauged the scale-up in the number of patients (overall and among 
those with CC) initiated on therapy and achieving SVR in the interferon-free DAA era (simplified to 
DAA era hereafter) compared to the pre-DAA era. In the context of this scale-up, we examined the 
temporal trend in new presentations for HCV-related DC in Scotland and assessed whether there had 
been any change in this trend – and, related to that, estimated the number of cases averted – since the 
introduction of DAAs. To corroborate this population-level analysis, we also undertook an individual-
level analysis which retrospectively followed up a national cohort with HCV-related cirrhosis to 
determine whether the risk of DC differed for those diagnosed with cirrhosis in the DAA era 
compared to prior to then. Supplementary file 1 includes an overview on the databases, record-linkage 
and analysis involved.  
 
Data Sources  
Scale-up in patients treated for HCV and achieving SVR 
Health Protection Scotland (HPS) collates national surveillance data on patients initiated onto HCV 
therapy for monitoring against government targets (in place since 2008)18. This is in the form of 
monthly reporting by NHS boards on aggregate numbers, in addition to individual-level data that are 
downloaded annually from standardised Clinical Databases installed in (17/18) specialist HCV 
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treatment centres across Scotland.7 Data held on the Clinical database includes HCV genotype, date of 
diagnosis with cirrhosis or hepatocellular carcinoma (HCC), date of HCV treatment initiation and 
completion, treatment regimen, and response to therapy. A diagnosis of cirrhosis is made based on 
standard clinical practice through a combination of liver biopsy, transient elastography, abdominal 
ultrasound, clinical examination and routine liver function tests.19,20 Data to the end of March 2018 
were used, enabling four (financial) years of treatment data pre and post introduction of DAAs, for 
analysis.   
 
New presentations for HCV-related DC 
National data on people who have ever been diagnosed with anti-HCV and their subsequent PCR 
results are also held at HPS, through collation of administrative data from the four laboratories 
undertaking all confirmation HCV antibody and PCR testing in Scotland.21 Through record-linkage of 
the Diagnosis database (to the end of 2018, involving 43,080 persons with anti-HCV) to morbidity 
and mortality databases, the number of people diagnosed with HCV and presenting to hospital with, 
or otherwise died from, DC in Scotland was determined.18,22 The hospital data, held by the 
Information Services Division (ISD), involves records of all general and acute inpatient/day-case 
hospital discharges in Scotland; discharge diagnoses were coded using the International Classification 
of Diseases (ICD)-9 during 1989-1995 and ICD-10 thereafter. Death registration data were provided 
by National Records of Scotland; underlying and contributing causes of death were coded using ICD-
9 during 1989-1999 and ICD-10 thereafter. Linkage of the Diagnosis database to the Scottish HCV 
Test (containing PCR and core-antigen test data since 1999)23 and Clinical databases (containing SVR 
status) was also undertaken to ascertain chronic HCV status at the time of DC presentation (described 
below). Further, linkage of the HCV Clinical database to morbidity and mortality databases afforded 
an opportunity to in addition examine presentations with HCV-related DC among a national cohort of 
people attending specialist HCV centres. The linkage exercise, approved by the Scottish Public 
Benefit and Privacy Panel, was performed by ISD in May 2019. All databases involved hold the 
Community Health Index number (a unique identifier allocated to each patient in NHS Scotland), 
which was used to link the Diagnosis database to, and retrieve records from, other databases (as 
described elsewhere).3,7,19  
 
Outcome Measures 
Scale-up in patients treated for HCV and achieving SVR 
The number, and characteristics, of patients initiated onto HCV therapy in Scotland in each financial 
year from April 2010 to March 2018 was ascertained through the Clinical database for 17/18 
specialist centres, supplemented with aggregate-level data reported to HPS for the remaining centre. 
We examined the proportion of patients achieving SVR, defined as testing PCR negative for viral 
RNA for a period of 12 or 24 weeks following completion of therapy, according to clinical guidelines 
We also estimated the number of people achieving SVR according to each financial year of treatment 
initiation, by combining the number of SVR cases where known with an estimate of SVR cases for 
those treatment initiations where SVR response was not known; for the latter, we applied the SVR 
rates (for those with a known response) to those who had completed their treatment course.   
New presentations for HCV-related DC: population-level analysis 
Presentations of HCV-related DC were defined as first-time admissions for DC among persons who 
had ever been diagnosed with chronic HCV infection and identified through the linkage of the 
Diagnosis database to the hospital data up to the end of 2018. Admission for DC referred to a 
hospitalisation with any of the following recorded in either the primary and/or secondary diagnostic 
fields: ascites (ICD-10: R18; ICD-9 789·5); bleeding oesophageal varices (ICD-10: I85·0, I98·3; ICD-
9 456·0); chronic or alcoholic hepatic failure, including hepatic encephalopathy (ICD-10: K70·4, 
K72·1, K72·9; ICD-9: 572·2, 572·8); and hepatorenal syndrome (ICD-10: K76·7; ICD-9: 572·4). 
These diagnosis codes were selected based on a previous validation exercise and have been applied in 
studies from Scotland and elsewhere.22,24 To reduce potential bias due to DC arising from a different 
aetiology, patients whose first DC admission occurred more than one year preceding their HCV 
diagnosis were excluded. Persons diagnosed with a history of chronic HCV was deduced through the 
PCR test data captured on the HCV diagnosis and test databases; those who had spontaneously 
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resolved their infection (i.e. PCR negative at time of their HCV diagnosis, with no subsequent record 
to indicate PCR positive) or whose PCR status was not known were excluded from analysis, whilst 
those who had cleared infection from HCV treatment were retained. In sensitivity analyses, we 
considered two broader definitions of HCV-related DC which additionally included either (a) those 
individuals who had not presented to hospital with DC but had otherwise died from DC (using the 
same set of ICD codes as above in relation to primary or secondary cause of death), or (b) those 
individuals diagnosed with anti-HCV but whose PCR status was not known. 
 
New presentations for HCV-related DC: individual-level analysis 
We also examined the risk of presentation with HCV-related DC (as described above) in the DAA 
compared to pre-DAA era at an individual-level through analysis of linked (hospital and deaths) data 
for a national cohort of patients with CC attending specialist HCV centres. The study population here 
was confined to patients who were recorded on the Clinical database as having chronic HCV and had 
been diagnosed with cirrhosis since January 2011; those with evidence of decompensation or HCC at 
baseline were excluded. We confined the pre-DAA era to a period (since 2011) when transient 
elastography (FibroScan®) was routinely used to diagnose cirrhosis, thereby minimising any bias 
arising through adoption of different modes of diagnosis across the study period.25 
 
Statistical Analysis  
Population-level analysis 
Segmented Poisson regression was used to assess the change in presentations of HCV-related DC 
nationally, following the introduction of DAAs.26 For the purpose of the modelling, presentations of 
HCV-related DC were split into six-monthly intervals, and categorised as pre-DAA (January 2000 to 
December 2014) and DAA (January 2015 to December 2018) eras.  A change point at the end of 2014 
was used in the model, allowing time for treatment initiation and completion (involving up to 24 
weeks of therapy initially) in the period immediately after the licencing of the first DAA (Sofosbuvir) 
in Scotland during June 2014.27 The segmented regression model estimates the temporal trend in 
presentations of HCV-related DC in both the pre-DAA and DAA eras, as well as the change in trend 
between the two periods. Results are presented as rate ratios (RR) with 95% CIs and associated p-
values. Models were performed for all patients, and stratified across a range of relevant factors (at DC 
presentation if not otherwise stated): sex, age (<50, 50+ years), DC diagnosis category (defined 
hierarchically in order of hepatic failure, ascites and bleeding varices based on previous work)3, 
presence of HCC (based on ICD-10 C22·0), chronic HCV status (based on linked HCV laboratory test 
and clinical data, as described above), and alcohol-related admission history (based on ICD diagnosis 
codes, as described elsewhere,24 in any hospital record up to and including the DC admission). We 
also examined the extent to which HCV was coded on the DC hospital record (based on ICD-10 
B17·1, B18·2), thereby providing insight as to the extent to which HCV-related DC would have been 
captured based solely on these data. Finally, we estimated the cumulative number of HCV-related 
cases averted with the introduction of DAAs, by subtracting the observed number from the 
counterfactual number – the latter predicted by the model based on the temporal trend before the 
introduction of DAAs – for the period 2015-18.  
 
Individual-level analysis 
Multifactorial Cox regression was used to estimate the risk of presentation with HCV-related DC 
among the national cohort of compensated cirrhotic patients, comparing those diagnosed with 
cirrhosis in a period preceding the introduction of new DAAs (January 2011 to May 2014) versus 
those diagnosed after (June 2014 to March 2018). Follow-up for each patient began at the date of 
cirrhosis diagnosis and ended at the earliest of the date of DC presentation, death, migration or 
administrative right-censoring date (31st March 2018). Covariates included in the regression were: 
sex, age group at cirrhosis diagnosis, risk group for HCV acquisition (person who injects drugs 
(PWID), non-PWID), alcohol consumption history (>50 units per week, ≤50 units per week/not 
known), genotype (1, 3, other/not known), antiviral treatment experience prior to cirrhosis diagnosis 
and Child-Pugh class (A, B). For the latter, the most recent laboratory test result (for bilirubin, 
albumin, and prothrombin) within 120 days of cirrhosis diagnosis was used.25 Multiple imputation 
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using chained equations was performed using the R package mice to impute missing data on risk 
group and laboratory measurements needed to compute Child-Pugh class.28,29   
 
Statistical analyses were conducted using R (version 3.5.1) and Stata (version 14).  
 
Results 
Scale-up in patients treated for HCV and achieving SVR 
Approximately 11000 patients had been initiated on HCV therapy in Scotland during the eight-year 
period 2010/11 to 2017/18 (Table 1), involving a 1·7-fold rise in initiates in the DAA compared to the 
pre-DAA period (Figure 1a).  Among patients diagnosed with CC, a greater scale-up of HCV 
treatment was observed, involving a 3.2-fold rise in the DAA compared to pre-DAA era (Figure 1b). 
The proportion of treatment initiations involving an interferon-free DAA regimen increased from 27% 
in 2014/15 to 72% in 2015/16, reaching 98% by 2017/18 (Table 1). 
Among 9237 patients initiated on HCV treatment during April 2010 to September 2018, 71% had 
achieved SVR (supplementary file 2). Confined to those where SVR status was known (87% of those 
treated), the proportion of treatment initiates achieving SVR rose from 76% in the pre-DAA era to 
94% in the DAA era. Among those with CC, this rise was more pronounced: increasing from 59% in 
the pre-DAA era to 92% in the DAA era. The scale-up in the estimated number of patients achieving 
SVR between the pre-DAA and DAA eras was 2·3-fold overall and 5·9-fold among those with CC 
(Figure 1).  
New presentations for HCV-related DC: Population-level analysis 
In the pre-DAA era, the annual number of presentations with HCV-related DC increased from 31 in 
2000 to 142 in 2014 (Figure 2). Since then (in the DAA era), the annual number had fallen to 69 in 
2018 (i.e. the lowest number for over a decade); this represents a 51% reduction among those with a 
history of chronic HCV. Considering only those with chronic HCV at the time of DC presentation, the 
number of DC presentations reduced by 67% between 2014 (127) and 2018 (42).      
The characteristics of patients presenting with HCV-related DC across the two eras were similar 
(Table 2a), except those presenting in the DAA era were older compared to the pre-DAA era (53% 
and 36% aged ≥50 years, respectively) consistent with an ageing cohort as reported elsewhere (and in 
the individual-level analysis, supplementary file 4).18 In addition, a higher proportion had already 
cleared HCV from therapy among those presenting in the DAA compared to pre-DAA era (25% and 
6%, respectively). The minority of DC presentations had HCV coded on their hospital record (39% in 
the pre-DAA and 42% in the DAA era).  
The number of HCV-related DC presentations was estimated to have increased 4% per six-month 
period in the pre-DAA era, and thereafter decreased 8% per six-months in the DAA era (Figure 2); 
this represents a significant change in trend for the DAA compared to pre-DAA era (RR 0·88, 95% CI 
0·85-0·90) (Table 2b). In sensitivity analysis, results were unchanged considering two broader 
definitions for HCV-related DC (supplementary file 3). An increasing trend in HCV-related DC was 
observed across all strata considered in the pre-DAA era (Table 2b); that trend changed significantly 
in the DAA era across most strata (according to sex, age groups, alcohol admission history and DC 
diagnosis categories), with the exception that no significant change was found for those who had 
HCV coded on the DC hospital record and those who had cleared HCV prior to DC presentation. 
Without the introduction of DAAs, the predicted annual number of HCV-related DC presentations 
was estimated to have increased to 208 by 2018, which translates to an estimated 330 cases averted 
with the introduction of DAAs during 2015-18 (Figure 2).  
New presentations for HCV-related DC: Individual-level analysis 
Among the national compensated cirrhotic cohort (n=2249), 55% were newly diagnosed in the DAA 
era, 74% were male, 38% aged ≥50 years, 64% PWID, 33% had a history of heavy alcohol use, 46% 
were genotype 3, 3% had Child-Pugh B, and 17% were treatment experienced (Table 3). These 
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characteristics were similar between those diagnosed with cirrhosis in the pre-DAA and DAA eras, 
with the exception of prior treatment experience (25% and 10%, respectively) (supplementary file 4). 
Compared to those diagnosed with cirrhosis in the pre-DAA era, patients diagnosed with cirrhosis in 
the DAA era had a significantly reduced risk of presenting with HCV-related DC (hazard ratio (HR) 




These findings provide the first evidence of a major population impact of DAAs in terms of averting 
HCV-related DC at a country-level. In line with the initial national strategy on DAAs in Scotland, 
scale-up of treatment was greatest for those with CC (the group at immediate risk of DC), and 
translated to a near six-fold rise in the estimated number of such patients clearing the virus and 
achieving SVR between the pre-DAA and DAA eras. This represents a level of change in DAA 
treatment uptake and clearance of infection that previous modelling work had predicted would yield 
an immediate reduction in the incident number of HCV-related DC.7 A halving in new presentations 
of DC among those with a history of chronic HCV has been observed within the first four years of 
DAAs; an even greater reduction of 67% was observed for those with chronic HCV at the time of 
presentation (i.e. excluding those who had received HCV therapy and were clear of their infection 
prior to presentation of DC). Our data provide compelling evidence to policymakers and practitioners 
that, in the context of an evidenced-based national plan, DAA treatment can rapidly revert an 
increasing tide of HCV-related DC.  
The above differential finding – vis-à-vis a 51% reduction among those with chronic HCV 
either currently or in the past versus 67% reduction among those with chronic HCV currently – was 
anticipated. Previous work has shown that heavy alcohol use, as well as other health risk behaviours 
known to accelerate liver disease progression, are prevalent in HCV-infected populations both in 
Scotland and elsewhere, and may compromise the clinical benefit of DAAs.20,24,30 New DC 
presentations among those who had cleared HCV from therapy almost doubled from 15 in 2014 to 27 
in 2018; 64% of the latter had an alcohol-related admission history. This rise reflects the considerable 
expansion of the compensated cirrhotic SVR population since the introduction of DAAs and residual 
risk of liver disease progression associated with alcohol and other risk behaviours. Overall, we found 
a similar significant change in the trend of DC presentations between the pre-DAA and DAA eras for 
both those with and without an alcohol history (captured through alcohol-related hospital episodes). 
Further, our individual-level analysis demonstrated a 45% reduced risk of presentation with DC for 
patients diagnosed with CC in the DAA era compared to those diagnosed in the pre-DAA era, 
adjusting for alcohol consumption history and other factors. Whilst our findings reinforce the need to 
address health risk behaviours in HCV infected and resolved populations (particular those with 
cirrhosis and at continued risk of liver failure and cancer), they also demonstrate that averting HCV-
related DC is possible even within sub-populations with a history of heavy alcohol use.  
Our results directly address the perspective that the real-world impact of DAA therapy 
remains unproven at the population level.11,12 Previously, data from Liver Transplant Registries in the 
United States and Europe have provided evidence of the early impact of DAAs, commensurate with 
our findings.31,32 Within the first two years of DAAs in Australia (via initially their compassionate 
access programme), a 21% reduction in presentations of HCV-related DC was observed at the state 
level of New South Wales among individuals diagnosed with anti-HCV; thus, a limitation was that 
individuals who had spontaneously resolved their HCV (over 25% of all diagnoses) were included in 
this trends analysis (as data on chronic infection and therapy were lacking), and may explain the lower 
rate of decline in the DAA era (3% per 6 months) compared to that observed for Scotland (8% per 6 
months).33 Individual-level analysis of a large multi-centre cohort study from France demonstrated 
that patients treated with DAAs, compared to those untreated, was associated with a decrease in all-
cause mortality and HCC but failed to find an association with DC (adjusted HR 1·14, 0·57-2·27; 
p=0.72).34 The lack of an association with DC could be due to limited statistical power, as only 106 
DC events were observed and their analysis relied on adjustment for 19 covariates in the multivariable 
model to explain the otherwise higher crude incidence of DC among those treated compared to 
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untreated.34 Both the population-level and individual-level analysis presented here from Scotland 
involved greater numbers of DC events (1706 and 219, respectively) to draw conclusions. Further, our 
individual-level analysis by design involved groups (i.e. those newly diagnosed with CC in the pre-
DAA and DAA eras) similar in nature and less prone to confounding issues as is evident with a 
treated to untreated comparison.  
The major strength of our study, unique to Scotland, is the availability of national data 
monitoring HCV diagnosis, treatment and disease, established in advance of the DAA era.17 Whilst 
many countries have adopted a similar DAA strategy to Scotland (vis-à-vis initially prioritising 
patients with advanced fibrosis), few have developed surveillance that can demonstrate population-
level impact of treatment, despite calls from WHO to invest in systems to monitor progress towards 
elimination of viral hepatitis.1,35 Without such surveillance, countries lack knowledge to inform the 
extent and nature of additional effort needed to prevent severe consequences of HCV.  
Our study is not without limitations. First, we rely on the ICD coding of DC and this could be 
subject to possible misclassification error. Our analysis reassuringly yielded a similar trend when 
stratified according to the major clinical indicators of DC (i.e. hepatic failure, ascites and bleeding 
varices). Importantly, we did not rely on the ICD coding of HCV on the hospital or death record as is 
well known to under-estimate HCV-related outcomes.36,37 Due to the severe nature of DC, almost all 
cases present to hospital, at which point HCV testing is (or has already been) performed, and so few 
presentations should be missed through our record-linkage approach. Second, we may have over-
estimated the number of HCV-related DC cases averted with DAAs if the assumed counterfactual for 
the period 2015-18 had not kept pace with the increasing trend for the fifteen-year period up to that 
point, but our assumption is in keeping with previous modelling work for Scotland which forecasted 
such a trajectory to at least 2020.2 Third, whilst a favourable change in HCV-related DC presentations 
was observed for those with a history of excess drinking, we cannot draw conclusions on whether this 
holds for those who continue to drink to excess. Fourth, other comorbidities influencing liver disease 
progression such as HIV and obesity, which are less prevalent in the Scottish HCV population20,22, 
would be worthy of study in other settings where these feature to a greater extent. Fifth, we confined 
our investigation to DC. Justification for this was to provide a thorough analysis for the leading cause 
of HCV-related mortality and the lack of an association between DAAs and DC by Carrat et al. meant 
a closer examination was warranted.34 Further, whilst a decline in new presentations of HCV-related 
DC was expected within the first few years of DAAs, population-level change in the incident number 
of  HCC cases and liver-related deaths may take longer to accrue (as these clinical endpoints stem not 
just from compensated cirrhosis, but also from more advanced liver disease) and thus longer follow-
up, than that considered here, would be beneficial to measure impact on these other outcomes; indeed, 
preliminary analysis shows the downturn in new presentations of HCV-related HCC and HCV-related 
liver deaths in Scotland occurred, subsequent to the fall in HCV-related DC, towards the end of the 
follow-up period in 2017 and 2018, respectively (supplementary file 5). Sixth, whilst we have 
examined the scale-up of DAAs and associated impact for a predominantly injecting drug use-related 
HCV epidemic, we have not considered those currently injecting separate from those who injected in 
the past. Data from a national survey in Scotland however show that appreciable scale-up of DAAs 
among the population continuing to inject drugs did not occur until towards the end of the study 
period considered here (during 2017-2018) and thus is the subject of an ongoing study to determine 
whether treatment leads to prevention benefit.38,39 
  In summary, this study provides evidence at the population-level of a major decline in 
presentations of HCV-related DC associated with the introduction of interferon-free DAAs. 
Compared to the pre-DAA era, patients diagnosed with cirrhosis in the DAA era have a significant 
reduced risk of progressing to DC. Our data underpin the new Scottish Government strategy and 
commitment to eliminate HCV by the end of 2024, involving reducing new presentations of DC 
among those with chronic HCV to less than ten per year, as well as reducing the prevalence of 
infection to below 0.1%.40,41 Whilst it remains to be seen as to whether we can eliminate HCV in 
Scotland within the next five years, we have nevertheless demonstrated that major progress in 
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Table 1  Characteristics of patients initiated onto HCV treatment in Scotland, in the four (financial) years prior to and post introduction of DAAs 
 
 Financial year (April to March) of HCV treatment initiation    
Total Pre-DAA era  DAA era 
2010/11 2011/12 2012/13 2013/14  2014/15 2015/16 2016/17 2017/18 
Total initiated, N1 1049 1002 1052 1054  1297 1782 1751 2082 11069 
Total initiated (and on clinical 
database1), N2 (% of N1) 
967 (92) 938 (94) 1014 (96) 943 (89)  1192 (92) 1642 (92) 1632 (93) 1924 (92) 10252 (93) 
Characteristics, n (% of N2) 
Sex Female  236 (24) 244 (26) 277 (27) 249 (26)  294 (25) 472 (29) 421 (26) 549 (29)    2742 (27) 




<35 303 (31) 267 (28) 259 (26) 272 (29)  212 (18) 213 (13) 219 (13) 297 (15)  2042 (20) 
35-49 498 (51) 506 (54) 538 (53) 500 (53)  590 (49) 777 (47) 857 (53) 1086 (57)  5352 (52) 
50+ 166 (17) 165 (18) 216 (21) 170 (18)  389 (33) 650 (40)  556 (34) 541 (28)  2853 (28) 
Genotype 1 411 (43) 359 (38) 485 (48) 428 (45)  519 (44) 948 (58)  905 (56) 926 (48)  4981 (49) 
3 496 (51) 507 (54) 450 (44) 432 (46)  558 (34) 565 (34)   578 (35) 840 (44)  4426 (43) 





No 867 (91) 829 (88) 855 (84) 792 (84)  800 (67) 1146 (70) 1222 (75) 1539 (80)  8050 (78) 
Yes 100 (10) 109 (12) 159 (16) 151 (16)  392 (33) 496 (30)  410 (25) 385 (20)  2202 (22) 
Treatment 
Regimen3 
IFN-Based 967 (100) 924 (99) 1000 (99) 907 (96)  416 (35) 210 (13)  117   (7) 17   (1)     4558 (44) 
IFN-Sparing 0  (NA) 6  (<1) 0 (NA) 15   (2)  450 (38) 251 (15) 151   (9) 16   (1) 889   (9)  
IFN-Free 0  (NA) 8  (<1) 14    (1) 21   (2)  326 (27) 1181 (72)  1364 (84) 1891 (98)  4805 (47) 
1 Data collated from 17/18 HCV treatment clinics in Scotland; aggregate data for the remaining clinic sourced for the Scotland total. 2 Data missing for 5 
patients. 3 IFN-Based includes pegylated interferon + ribavirin ± telaprevir/boceprevir; IFN-Sparing includes pegylated interferon + ribavirin + sofosbuvir; 
pegylated interferon + ribavirin + simeprevir; IFN-Free includes any treatment regimen not containing interferon.                                                                




*DC diagnosis category was defined using a hierarchy of ICD-10 codes, ranked in order of hepatic failure, ascites and then bleeding varices.                                      
RR, relative risk; CI, confidence interval; DAA, direct-acting antiviral;  DC, decompensated cirrhosis; HCV, hepatitis C virus; HCC, hepatocellular 
carcinoma; SVR, sustained viral response. 
 
Table 2 a) Characteristics of patients newly presenting with HCV-related decompensated cirrhosis (DC) in the pre-DAA and DAA eras, and b) 
Results of segmented Poisson regression analyses modelling the trend in the (6-monthly) number of new presentations with HCV-related DC 








a) New presentations with  
HCV-related DC,  
N (%) 
b) Segmented Poisson regression analysis 
Pre-DAA 
Era 
(Jan 2000 to 
Dec 2014) 
DAA             
Era 
(Jan 2015 to 
Dec 2018) 
Pre-DAA Era Slope 
per 6-month period 
Change in Slope  
 (DAA vs pre-DAA Era) 
DAA Era Slope 
per 6-month period 
RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value 
Total 1302 (100) 404 (100) 1.04 (1.04–1.05) <0.001 0.88 (0.85–0.90) <0.001 0.92 (0.89–0.94) <0.001 
Sex 
  
Female 333 (26) 112 (28) 1.05 (1.04–1.06) <0.001 0.86 (0.81–0.91) <0.001 0.90 (0.85–0.95) <0.001 
Male 969 (74) 292 (72) 1.04 (1.03–1.05) <0.001 0.88 (0.85–0.91) <0.001 0.92 (0.89–0.95) <0.001 
Age <50 827 (64) 191 (47) 1.04 (1.03–1.04) <0.001 0.85 (0.81–0.88) <0.001 0.88 (0.84–0.91) <0.001 




No 655 (50) 183 (45) 1.04 (1.03–1.05) <0.001 0.87 (0.83–0.91) <0.001 0.90 (0.87–0.94) <0.001 
Yes 
647 (50) 221 (55) 1.05 (1.04–1.06) <0.001 0.88 (0.84–0.91) <0.001 0.92 (0.89–0.96) <0.001 
HCV coded at DC 
admission 
No 795 (61) 236 (58) 1.06 (1.05–1.07) <0.001 0.82 (0.79–0.86) <0.001 0.87 (0.84–0.90) <0.001 





Failure 461 (35) 147 (36) 1.04 (1.03–1.05) <0.001 0.88 (0.84–0.93) <0.001 0.92 (0.88–0.96) <0.001 
Ascites 690 (53) 207 (51) 1.05 (1.04–1.06) <0.001 0.87 (0.84–0.91) <0.001 0.91 (0.88–0.94) <0.001 
Bleeding 
Varices 151 (12) 50 (12) 1.04 (1.02–1.05) <0.001 0.89 (0.81–0.97) 0.006 0.92 (0.85–0.99) 0.03 
HCC at time of DC 
admission 
No 1204 (92) 352 (87) 1.04 (1.04–1.05) <0.001 0.87 (0.84–0.90) <0.001 0.91 (0.88–0.93) <0.001 
Yes 98 (8) 52 (13) 1.07 (1.04–1.10) <0.001 0.91 (0.83–0.99) 0.028 0.97 (0.90–1.04) 0.39 
Chronic HCV 
status at time of 
DC  
Chronic 1220 (94) 304 (75) 1.04 (1.03–1.05) <0.001 0.84 (0.81–0.87) <0.001 0.88 (0.85–0.90) <0.001 
 
Cleared 82 (6) 100 (25) 1.07 (1.03–1.10) <0.001 1.02 (0.94–1.11) 0.58 1.09 (1.03–1.16) 0.003 
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Table 3 a) Characteristics of chronic HCV infected patients diagnosed with compensated cirrhosis in Scotland between 1 January 2011 and 31 
March 2018, b) number (and rate) of  and c) hazard ratio for new presentation with HCV-related DC among this cirrhotic population according 
to DAA era of cirrhosis diagnosis and other covariates. 
 a) Cirrhosis population b) New presentation with 
HCV-related DC 
c) Hazard ratio (HR) for  
new presentation with  
HCV-related DC (95% CI) 
N (%) Person-years n Rate (per 100 
person-years) 
Unadjusted Adjusted 
All patients 2249 (100) 6738 219 3·25 – – 
Diagnosed with 
cirrhosis 
Pre-DAA era 1015 (45) 4529 159 3·51 1·00 1·00 
DAA era 1234 (55) 2209 60 2·72 0·59 (0·43-0·80) 0·55 (0·40-0·76) 
Sex Female   584 (26) 1769 59 3·33 1·00 1·00 
Male 1665 (74) 4969 160 3·22 0·96 (0·71-1·30) 0·93 (0·68-1·27) 
Age at cirrhosis 
diagnosis (years) 
<50 1402 (62) 4331 122 2·82 1·00 1·00 
50+   847(38) 2407 97 4·03 1·40 (1·07-1.83) 1·61 (1·19-2·20) 
Past/current risk 
group  
PWID 1448 (64) 4304 129 3·00 1·00 1·00 
Non-PWID   348 (15) 1166 36 3·09 1·08 (0·77-1·50) 0·96 (0·63-1·46) 
Not known*   453 (20) 1268 54 4·26 – – 
Alcohol 
consumption history 
>50 units/wk   743 (33) 2207 102 4·62 1·78 (1·37-2·32) 1·67 (1·26-2·20) 
≤50 units/wk (and 
not known) 
1506 (67) 4531 117 2·58 1·00 1·00 
Genotype G1   930 (41) 2752 92 3·34 1·09 (0·82-1·45) 1·03 (0·77-1·38) 
G3 1041 (46) 3243 98 3·02 1·00 1·00 
Other/NK   278 (12) 743 29 3·90 1·27 (0·84-1·92) 1·01 (0·65-1·57) 
Child-Pugh class A 1556 (69) 4752 131 2·76 1·00 1·00 
B    62   (3) 134 14 10·47 4·03 (2·14-7·59) 3·95 (1·98-1·57) 
Not known* 631 (28) 1852 74 4·00 – – 
Prior antiviral 
treatment  
Naïve 1876 (83) 5177 176 3·40 1·00 1·00 
Experienced  373 (17) 1562 43 2·75 0·86 (0·62-1·21) 0·75 (0·52-1·06) 
*  Category not used in Cox regression as missing values were imputed (see Methods).  
 
   
 
Figure 1  Number of people initiated on HCV therapy and the estimated number achieving SVR in Scotland by financial year (April to 
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Figure 2  Observed and predicted number of new presentations for HCV-related decompensated cirrhosis  (DC)  in Scotland 
during the pre-DAA (2000-2014) and DAA (2015-2018) eras. 
Pre-DAA era slope:
4% increase per 6-month
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DAA era slope:
8% decrease per 6-month






HCV in Scotland, 




Scottish HCV Test database 
(all HCV tests (including 
PCR and Antigen) from the 
four main HCV testing 





Scottish HCV Clinical database 
(all persons referred to (17/18) 
specialist HCV treatment 
centres in Scotland, 




Scottish hospital database 
(records of all general and 
acute inpatient/day-case 
hospital discharges in 
Scotland, 
up to Dec 2018)
(100% with CHI*)
Database (v)
Scottish deaths register 
(all deaths in Scotland, 
up to Dec 2018)
(100% with CHI*)
Results generated from analysis of the HCV Clinical database:
Table 1: Characteristics of patients  treated (Apr 2010 to Mar 2018)
Suppl file 2: Proportion of patients achieving SVR (Apr 2010 to Sep 2017)
Figure 1: Scale-up of patients treated and achieving SVR
Linked data (including HCV test 
and clinical data, as well as 
hospital and deaths data) for 
persons on the Scottish HCV 
Diagnosis database
Sub-cohort extracted from the 
HCV Clinical database on all 
patients with chronic HCV 
infection diagnosed with 
compensated cirrhosis during 
Jan 2011 to Mar 2018, with 
linked hospital and death 
records
Results generated from analysis of the Linked data :
Table 2: Patients  presenting with HCV-related DC (Jan 2000 to Dec 2018)
Figure 2: Trend in presentations with HCV-related DC (2000 to 2018)
Suppl file 3: Sensitivity analysis on definition of HCV-relate d DC
Results generated from analysis of the Sub-cohort 
of patients with compensated  cirrhosis:
Table 3: Hazard ratio for HCV-related DC according 
to DAA era and other characteristics
Suppl file 4: Characteristics of patients according to 
DAA era
Supplementary file 1: Overview of the five national surveillance databases and associated record-linkage involved (indicated by double 
sided arrows) and analysis/results generated as part of this study. 
* All databases involved hold the Community Health Index (CHI) number, which is a unique identifier allocated to each patient on first registration 
with NHS Scotland. Not all records held on the HCV databases will include the CHI number, if not reported from certain settings (e.g. sexual health
clinics). As described elsewhere, the CHI number on the Diagnosis database was used to link and retrieve records from the other databases.7 
 Supplementary file 2  Proportion of patients achieving a sustained viral response (SVR) among those initiated on (and with a known response 
to) HCV treatment in Scotland, by patient characteristics and financial year 
 Financial year (April to March) of HCV treatment initiation  
Pre-DAA era  DAA era 
2010/11 2011/12 2012/13 2013/14  2014/15 2015/16 2016/17 2017/18
                
(Apr-Sep)2 
Total initiated (and on clinical 
database) (N1) 967  938 1014 943 
 
1192 1642 1632 
 
909 
Proportion with a known response 
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 IFN-Based includes pegylated interferon + ribavirin ± telaprevir/boceprevir ; IFN-Sparing includes pegylated interferon + ribavirin + sofosbuvir; pegylated 
interferon + ribavirin + simeprevir ; IFN-Free includes any treatment regimen not containing interferon. 2 Data relating to those initiated in the first six 
months of 2017/18 financial year presented, to allow a minimum of six-months follow-up time to capture SVR status on the clinical database.                         




Supplementary file 3  Results of sensitivity analysis for the segmented regression analysis, considering two broader definitions for the outcome 








a) New presentations with 
HCV-related DC,  
N (%) 
b) Segmented Poisson regression analysis 
Pre-DAA 
Era 
(Jan 2000 to 
Dec 2014) 
DAA             
Era 
(Jan 2015 to 
Dec 2018) 
Pre-DAA Era Slope  
per 6-month period 
Change in Slope 
per 6-month period            
DAA Era Slope  
per 6-month period 
RR (95% CI) p-value RR (95% CI) p-value RR (95% CI) p-value 
i) First-time hospital 
admission with (or 
otherwise death from) 
DC, among those with 
chronic HCV diagnosis 
1415 451 1.04 (1.04–1.05) <0.001 0.89 (0.86 –0.91) <0.001 0.92 (0.90–0.95) <0.001 
ii) First-time hospital 
admission with DC, 
among those with 
chronic HCV diagnosis 
(including those with 
not known chronic 
status at diagnosis) 
1366 412 1.04 (1.03–1.05) <0.001 0.88 (0.86 – 0.91) <0.001 0.92 (0.90–0.94) <0.001 
  
 
Supplementary file 4  Characteristics of chronic HCV infected patients with compensated 
cirrhosis in Scotland according to whether diagnosed with cirrhosis during the pre-DAA era 
(January 2011 to May 2014) or in the DAA era (June 2014 to March 2018) 




Total 1015 (100) 1234 (100) 
Sex Female 275  (27) 309  (25) 
Male 740  (73) 925  (75) 
Age at cirrhosis 
diagnosis (years) 
<50 661 (65) 741 (60) 
50+ 354 (35) 493 (40) 
Risk group for HCV 
acquisition 
PWID 639  (63) 809  (66) 
Non-PWID/not known 376  (37) 425  (34) 
Alcohol consumption 
history 
>50 units/wk 350  (34)    393  (32) 
≤50 units/wk (and not 
known) 
665 (66) 841 (68) 
Genotype G1 398 (39) 532 (43) 
G3 491 (48) 550 (45) 
Other/NK 126 (12) 152 (12) 
Child-Pugh class A 706 (70)  850 (69) 
B   26   (3)   36   (3) 
Not known 283 (27) 348 (28) 
Prior antiviral 
treatment  
Naïve 766 (75) 1110 (90) 








DC HCC Liver-related Death
Supplementary file 5:  Observed number of i) new presentations of HCV-related decompensated cirrhosis  (DC) , ii) new 
presentations of HCV-related hepatocellular carcinoma (HCC), and iii) HCV-related liver* deaths (i.e. involving either DC and/or
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* Liver-related refers to death involving either DC and/or HCC. 
